Stockscreener 앱 받기
12.72
5.91%
0.71
시간 외 거래:
12.66
-0.06
-0.47%
전일 마감가:
$12.01
열려 있는:
$12.07
하루 거래량:
391.17K
Relative Volume:
0.90
시가총액:
$393.39M
수익:
$72.35M
순이익/손실:
$-45.34M
주가수익비율:
-8.0993
EPS:
-1.5705
순현금흐름:
$-32.43M
1주 성능:
+7.43%
1개월 성능:
+18.22%
6개월 성능:
+242.86%
1년 성능:
+132.54%
1일 변동 폭
$12.02
$12.76
1주일 범위
$11.34
$12.76
52주 변동 폭
$3.22
$12.76
Avita Medical Inc Stock (RCEL) Company Profile
명칭
Avita Medical Inc
전화
661-568-1317
주소
28159 AVENUE STANFORD, VALENCIA, CA
Compare RCEL vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCEL
Avita Medical Inc
|
12.72 | 366.17M | 72.35M | -45.34M | -32.43M | -1.5705 |
ABT
Abbott Laboratories
|
97.50 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-05 | 개시 | Northland Capital | Outperform |
| 2025-11-20 | 업그레이드 | BTIG Research | Sell → Neutral |
| 2025-08-08 | 다운그레이드 | BTIG Research | Neutral → Sell |
| 2024-12-24 | 개시 | D. Boral Capital | Buy |
| 2024-04-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-06-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-02 | 개시 | Piper Sandler | Overweight |
| 2020-08-27 | 개시 | BofA Securities | Buy |
| 2020-04-21 | 개시 | Oppenheimer | Outperform |
| 2020-03-03 | 개시 | BTIG Research | Buy |
모두보기
Avita Medical Inc 주식(RCEL)의 최신 뉴스
AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs Balance Sheet – HAN:51KB - TradingView
AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs Revenue Breakdown – HAN:51KB - TradingView
Basic earnings per share (basic EPS) of AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs – HAN:51KB - TradingView
Liquidity Mapping Around (RCEL) Price Events - Stock Traders Daily
Avita Medical (RCEL) Slips 1.78% to $11.02 as Shares Drift Toward Lower SupportBreakout Stock Alerts - dars.gov.et
Avita Medical Notifies Cessation of 5,499 Unquoted Options Following Lapse of Conditions - Kalkine
What Lies Ahead for Avita Medical (ASX:AVH) as Commercial Growth Progresses in 2026? - Kalkine
Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Avita Medical Inc. Discloses CDI and Securities Statement for August 2026 - Kalkine
Avita Medical Issues 18,293 Restricted US Stock Units to Key Management Personnel - Kalkine
Avita Medical Issues 25,213 Unquoted Options Expiring August 2036 Under Employee Incentive Scheme - Kalkine
Avita Medical Issues 17,151 Common Stock Securities Following Multiple Option Conversions - Kalkine
Precision Trading with Avita Medical Inc. (RCEL) Risk Zones - Stock Traders Daily
564,952 Shares in Avita Medical Inc. $RCEL Bought by BlackRock Inc. - MarketBeat
Avita Medical Stock Price Forecast. Should You Buy RCEL? - StockInvest.us
RCEL stock gains on fresh price data while Avita Medical readies next steps - AD HOC NEWS
Gross margin % of AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs – HAM:51KB - TradingView
AVITA Medical to Showcase Leadership at Lake Street and Morgan Stanley Healthcare Conferences in September 2026 - kalkinemedia.com
Net current asset value per share of AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs – HAM:51KB - TradingView
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference - Investing News Network
Avita Medical Inc.ADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
A live webcast will carry AVITA Medical’s Sept. 16 conference discussion. - Stock Titan
AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs Balance Sheet – HAM:51KB - TradingView
51KB Stock Price and Chart — HAM:51KB - TradingView
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy - Yahoo Finance
Lake Street Maintains Avita Medical(RCEL.US) With Buy Rating, Raises Target Price to $12 - Moomoo
RCEL | Avita Medical, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Why Is AVITA Medical (ASX: AVH) Stock Up Over 100% in a Month? PermeaDerm Study Results Fuel the Rally - Kalkine
AVITA Medical: Favorable Reimbursements For Skin Wound Care (NASDAQ:RCEL) - Seeking Alpha
Broker puts fresh buy ratings and tips 36% upside for these earnings results winners - The Motley Fool Australia
Avita Medical (RCEL) Stock Forum and Discussion - Moomoo
RCEL Maintained by TD Cowen -- Price Target Raised to $14.00 - GuruFocus
TD Cowen raises Avita Medical stock price target on PermeaDerm data - Investing.com Canada
RCEL Maintained by BTIG -- Price Target Raised to $11.00 - GuruFocus
AVITA Medical (NASDAQ:RCEL) Raises Full-Year Guidance on Spray-On Skin Adoption - Kalkine Media
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
BTIG raises Avita Medical stock price target on positive trial data - Investing.com Canada
TD Cowen Maintains Avita Medical(RCEL.US) With Buy Rating, Raises Target Price to $14 - Moomoo
AVITA Medical (ASX:AVH) Soars 22.73% as Revenue Upgrade and Cash-Flow Target Reset the Conversation - Kalkine
Avita Medical Inc. (NASDAQ:RCEL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
AVITA Medical (ASX:AVH) Jumps 23.18% as Shares Extend a 67% One-Year Recovery - Kalkine
AVITA Medical (ASX: AVH) Reports 70% Cost Advantage for PermeaDerm in Randomized Study - Kalkine
Avita Medical Says Clinical Study for Biosynthetic Wound Matrix Meets Primary Endpoint - marketscreener.com
AVITA Medical's PermeaDerm-I Study Reveals 70% Cost Savings Over Cadaveric Allograft with Equivalent Clinical Results - Kalkine Media
AVITA Medical Inc to Host Key Opinion Leader Webinar Transcript - GuruFocus
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes - Investing News Network
RCEL Looks 21.8% Undervalued on GF Value™ - GuruFocus
Avita Medical Says PermeaDerm Study Meets Primary Endpoint, Showing 70% Cost Reduction - marketscreener.com
AVITA Medical’s PermeaDerm shows 70% cost savings over allograft By Investing.com - Investing.com Canada
A wound matrix cut prep time 96% with outcomes comparable to cadaver grafts - Stock Titan
Avita Medical Inc (RCEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Avita Medical Inc 주식 (RCEL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Woody Joseph Fralin | Director |
Jun 09 '26 |
Buy |
4.19 |
10,000 |
41,900 |
102,761 |
| Woody Joseph Fralin | Director |
Jun 03 '26 |
Buy |
4.09 |
10,000 |
40,949 |
92,761 |
| Woody Joseph Fralin | Director |
Jun 01 '26 |
Buy |
4.30 |
10,000 |
43,000 |
10,000 |
| Woody Joseph Fralin | Director |
Jun 02 '26 |
Buy |
4.19 |
10,000 |
41,936 |
20,000 |
| O'Toole David D | CFO |
May 20 '26 |
Buy |
4.26 |
2,000 |
8,520 |
145,927 |
| O'Toole David D | CFO |
May 19 '26 |
Buy |
4.24 |
2,000 |
8,480 |
143,927 |
| O'Toole David D | CFO |
Feb 19 '26 |
Buy |
4.15 |
3,000 |
12,450 |
140,127 |
0.26%
0.38%
자본화:
|
볼륨(24시간):